Author details

Full Name

Anne Barton

Affiliation

ORCID

Career Start Year

1999

Papers

296

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37516563	Genetic Studies Investigating Susceptibility to Psoriatic Arthritis: A Narrative Review.		2023
36243888	Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?	Pharmacogenomics J	2023
35861400	Association between psoriatic disease and lifestyle factors and comorbidities: cross-sectional analysis and Mendelian randomization.	Rheumatology	2023
38010198	Using polygenic risk scores to aid diagnosis of patients with early inflammatory arthritis: results from the Norfolk Arthritis Register.		2023
37979960	Expression quantitative trait loci analysis in rheumatoid arthritis identifies tissue specific variants associated with severity and outcome.		2023
37563062	Utility of Musculoskeletal Ultrasound in Psoriatic Arthritis.		2023
38070158	Non-trough serum drug levels of adalimumab and etanercept are associated with response in patients with psoriatic arthritis.		2023
37699653	HLA-DRB1 and HLA-DQA1 associated with immunogenicity to adalimumab therapy in patients with rheumatoid arthritis.		2023
37873414	GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets.	medRxiv	2023
37694182	Application of clinical and molecular profiling data to improve patient outcomes in psoriatic arthritis.	Ther Adv Musculoskelet Dis	2023
36716083	Identification of Cell-Specific Differential DNA Methylation Associated With Methotrexate Treatment Response in Rheumatoid Arthritis.		2023
37267152	Socioeconomic deprivation is associated with reduced response and lower treatment persistence with TNF inhibitors in rheumatoid arthritis.		2023
36810200	Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis.		2023
37389432	A proteomics study of rheumatoid arthritis patients on etanercept identifies putative biomarkers associated with clinical outcome measures.		2023
37321637	The Effect of COVID-19 on Medication Adherence in a Rheumatoid Arthritis (BRAGGSS) and Psoriatic Arthritis (OUTPASS) UK Cohort.	J Rheumatol	2023
36942637	Development of a sensitive biochemical assay for the detection of tofacitinib adherence.		2023
36696131	Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study.		2023
36600188	Genetically proxied TYK2 inhibition is associated with reduced sarcoidosis susceptibility.		2023
34142326	Towards Personalising the Use of Biologics in Rheumatoid Arthritis: A Discrete Choice Experiment.	Patient	2022
36371989	Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity.	EBioMedicine	2022
35507331	Comparative Genetic Analysis of Psoriatic Arthritis and Psoriasis for the Discovery of Genetic Risk Factors and Risk Prediction Modeling.	Arthritis Rheumatol	2022
36289648	Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis.	Biomedicines	2022
35377444	Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy.	Rheumatology (Oxford)	2022
36333501	Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis.	Nat Genet	2022
35995490	Separating the effects of childhood and adult body size on inflammatory arthritis: a Mendelian randomisation study.	RMD Open	2022
35468805	HLA-DRB1 haplotypes predict cardiovascular mortality in inflammatory polyarthritis independent of CRP and anti-CCP status.		2022
34384350	Robust optimization of SWATH-MS workflow for human blood serum proteome analysis using a quality by design approach.	Clinical Proteomics	2021
34074658	Proceedings of the 2020 GRAPPA Collaborative Research Network (CRN) Meeting.	J Rheumatol Suppl	2021
33964978	Correction to: Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment.		2021
33691749	Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment.		2021
33790392	Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics.	Scientific Reports	2021
34096881	Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes.	Ann Rheum Dis	2021
33605404	Do people with rheumatoid arthritis maintain their physical activity level at treatment onset over the first year of methotrexate therapy?	Rheumatology	2021
33820439	Cell-specific epigenetic drivers of pathogenesis in rheumatoid arthritis.	Epigenomics	2021
32596718	Translating research into clinical practice: quality improvement to halve non-adherence to methotrexate.	Rheumatology	2021
33188696	Changes in the illness perceptions of patients with rheumatoid arthritis over the first year of methotrexate therapy.	Rheumatology	2021
33184488	Machine learning in precision medicine: lessons to learn.	Nature reviews. Rheumatology	2021
31329972	Adding value to real-world data: the role of biomarkers.	Rheumatology	2020
32203228	Correction: A restricted spectrum of missense KMT2D variants cause a multiple malformations disorder distinct from Kabuki syndrome.	Genet Med	2020
31598719	Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis.	Rheumatology	2020
31790148	The use of missing values in proteomic data-independent acquisition mass spectrometry to enable disease activity discrimination.	Bioinformatics	2020
31949313	A restricted spectrum of missense KMT2D variants cause a multiple malformations disorder distinct from Kabuki syndrome.	Genet Med	2020
31729526	Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as 'satisfactory'.	Rheumatology	2020
32176556	Personalized medicine in rheumatic diseases: how close are we to being able to use genetic biomarkers to predict response to TNF inhibitors?	Expert Review of Clinical Immunology	2020
31945409	Lymphocyte DNA methylation mediates genetic risk at shared immune-mediated disease loci.	Journal of Allergy and Clinical Immunology	2020
31819160	Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients.	Pharmacogenomics Journal	2020
32097471	Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis.	Rheumatology	2020
32475078	Latent Class Trajectory Modeling of 2-Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic Drugs.	Arthritis Rheumatol	2020
32864695	Predicting treatment response to IL6R blockers in rheumatoid arthritis.	Rheumatology	2020
33239102	Genetic feature engineering enables characterisation of shared risk factors in immune-mediated diseases.	Genome Medicine	2020